Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca [TheStreet.com]
AstraZeneca PLC Ordinary Shares (AZN)
Last astrazeneca plc ordinary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: TheStreet.com
CAMBRIDGE, Mass. April 29, 2026 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree"), a biotechnology company pioneering next-generation targeted protein degradation approaches for cancer and other serious diseases, today announced that AstraZeneca (LSE/STO/NYSE: AZN) has exercised its option under the companies' previously announced agreement to obtain an exclusive global license to develop and commercialize PTX-299, a first-in-class bispecific antibody degrader targeting EGFR. The option exercise follows encouraging preclinical progress and represents an important milestone in the collaboration between the two companies. Under the terms of the agreement, AstraZeneca will assume responsibility for global development and commercialization of the therapeutic candidate. "This milestone marks an important validation of our AbReptor™ platform," said Hojuhn Song, Ph.D., Founder and CEO of Pinetree Therapeutics. "We are pleased that AstraZeneca has exercised its option to advance P
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC Ordinary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca [Yahoo! Finance]Yahoo! Finance
- Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZenecaPR Newswire
- AstraZeneca results: Q1 2026Business Wire
- BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and olderBusiness Wire
- SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosusBusiness Wire
AZN
Sec Filings
- 4/29/26 - Form 6-K
- 4/28/26 - Form SCHEDULE
- 4/28/26 - Form 6-K
- AZN's page on the SEC website